Express study on the relationship between dulaglutide and "erectile dysfunction"

Yimaitong compiles and organizes, please do not reprint without authorization
.

Diabetes is the main risk factor for erectile dysfunction in men, but the effect of the new hypoglycemic drug glucagon-like peptide-1 receptor agonist (GLP-1RA) on erectile function is still unclear
.

Recently, the Lancet published a study in which some scholars explored the relationship between dulaglutide and erectile dysfunction in men with type 2 diabetes
.

 Diabetes is the main risk factor for erectile dysfunction, but the effect of GLP-1RA on erectile function is unclear
.

We aimed to evaluate the incidence, prevalence and progression of erectile dysfunction in men treated with dulaglutide compared with placebo, and to determine whether the effect of dulaglutide on erectile dysfunction is related to other diabetes-related outcomes The impact is the same
.

 Introduction to the REWIND Study The REWIND study is a double-blind, placebo-controlled randomized trial, which aims to explore the effect of adding dulaglutide to conventional treatment on major adverse cardiovascular events in patients with type 2 diabetes, in 371 cases in 24 countries Locations to complete
.

 The study used a randomized double-blind parallel group design and included 9901 patients with type 2 diabetes aged ≥50 years, including confirmed clinical vascular disease (≥50 years old), subclinical vascular disease (≥55 years old), or at least two types of heart disease.
Subjects with vascular risk factors (≥60 years old)
.

The subjects were randomly divided into two groups.
On the basis of conventional hypoglycemic treatment, 1.
5 mg dulaglutide was injected subcutaneously, once a week, or placebo treatment.
The average follow-up time was 6.
5 years
.

The primary endpoint is the composite endpoint consisting of the first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke
.

Secondary endpoints include microvascular complications, hospitalization for angina, all-cause mortality, hospitalization for heart failure
.

 Long-term use of dulaglutide may reduce the incidence of erectile dysfunction.
Some male subjects filled out the International Index of Erectile Function Questionnaire (IIEF) at baseline, 2 years, 5 years, and the end of the study.
On the basis of these data, Researchers conducted this exploratory analysis.
The main result of the study was that the first moderate or severe erectile dysfunction event occurred after randomization, which was evaluated by the IIEF score
.

 From August 18, 2011 to August 14, 2013, 3,725 (70.
1%) of the 5,312 male participants with an average age of 65.
5 years were analyzed, of which 1,487 (39.
9%) had a history of cardiovascular disease, and 2,104 First name (56.
5%) had moderate or severe erectile dysfunction at baseline
.

 After randomization, the incidence of erectile dysfunction was 21.
3/100 person-years in the dulaglutide group and 22.
0/100 person-years in the placebo group (HR 0.
92, 95% CI 0.
85-0.
99, p=0.
021)
.

Compared with the placebo group, men in the dulaglutide group had a smaller decline in erectile function scores
.

 Researchers believe that long-term use of dulaglutide may reduce the incidence of moderate to severe erectile dysfunction in men with type 2 diabetes
.

 Yimaitong compiled and compiled from: Bajaj HS, Gerstein HC, Rao-Melacini P, et al.
Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.
The lancet.
Diabetes & endocrinology.
2021 Jun 18.
DOI:10.
1016/S2213-8587(21)00115-7,PMID:34153269.